Adial Pharmaceuticals, Inc. Derivative Underlying Investment Principal
Adial Pharmaceuticals, Inc. (ADIL) had Derivative Underlying Investment Principal of $51.5 as of 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Notes › SEC Schedule
us-gaap:DerivativeUnderlyingInvestmentPrincipal · last filed 2024-04-01
- 2023-12-31: Derivative Underlying Investment Principal $51.50.
| Period end | Derivative Underlying Investment Principal |
|---|---|
| 2023-12-31 | $51.50 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |